Citi: Sino Biopharmaceutical's Acquisition of Hygieia Enhances Innovation Capabilities and Licensing Potential; Rated 'Buy'

Gelonghui January 15 | Citi issued a research report stating that Sino Biopharmaceutical Co., Ltd. announced the acquisition of Hygieia, a private biotech company focused on small interfering RNA (siRNA) drugs, for a maximum base consideration of 1.2 billion yuan. Through this acquisition, Sino Biopharm will establish a next-generation cardiovascular innovation pipeline, strengthen its presence in weight management and metabolic diseases, and expand into new frontiers of the chronic disease management market. The bank believes that this acquisition further enhances Sino Biopharm's innovation capabilities and out-licensing potential, solidifying its position as a leader among China’s innovative pharmaceutical companies. The target price is set at HK$10.8 with a "Buy" rating.